Skip to content
Open access

Development of a Potent QS-21-Derived Adjuvant Photoaffinity Probe: Identification of Cathepsin D as the Molecular Receptor.

Oct 2026 · Angewandte Chemie · pp. e5055772 · 0 citations · 27 references
Medicine

TL;DR

Novel saponin photoaffinity probes are developed for molecular target identification, merging synthetic chemistry, photoaffinity labeling, and chemical proteomics and enable identification of Cathepsin D (CatD) as the selective receptor driving saponin adjuvant effects.

Abstract

The saponin natural product QS-21 is a potent immunological adjuvant used in human vaccines to enhance the immune response but suffers from scarcity, instability, and dose-limiting toxicity, precluding its advancement as a stand-alone adjuvant. Further, putative cellular receptor(s) and its molecular mechanisms of action are unknown, which has prevented the rational design of saponin adjuvants, emphasizing the need for discovering these receptors and elucidating mechanisms. Herein, we have developed novel saponin photoaffinity probes for molecular target identification, merging synthetic chemistry, photoaffinity labeling, and chemical proteomics. One of these potent adjuvants generated superior antibody responses to QS-21 with less toxicity and enabled identification of Cathepsin D (CatD) as the selective receptor driving saponin adjuvant effects. Binding to surface-exposed CatD, lipid raft interactions, and lysosomal acidification were shown to be key for CatD-mediated saponin-induced immune activation, whereas neither photocrosslinking nor apparent binding was observed in comparative experiments with other lysosomal cathepsins, confirming the specificity of the interaction. These studies highlight the promise of this saponin probe as a potent vaccine adjuvant, unveiling CatD as the molecular target. This breakthrough sets the stage for elucidating the precise mechanisms of saponin immunopotentiation, facilitating rational adjuvant design and development of optimized adjuvant-antigen combinations for future vaccines.

Read PDF

Similar papers

Review Nov 2026

From Natural Products to Chemical Probes: Discovery, Design, and Biological Insight.

Macrocyclic natural products possess conformationally defined structures that enable recognition of complex biomolecular surfaces, making them attractive scaffolds for modulating protein-protein interactions (PPIs). In this review, I highlight how chemical probes derived from marine natural products have uncovered new...

Masaki Kita · 0 citations
Open access Sep 2026

Development of G Protein-Coupled Receptor 183 Benzimidazole Antagonists Utilizing a Core-Hopping Approach

G protein-coupled receptor 183 (GPR183, EBI2) has emerged as a promising therapeutic target for neuropathic pain due to its role in neuroinflammatory signaling. Previously, our group identified SAE-14 as a potent GPR183 antagonist and lead scaffold for analgesic development. To further explore the structural requiremen...

Angelina Ellis, Israel I. Olayide, Vanja Kalajdzic et al. · 0 citations
Review Oct 2026

Recent advances in the design, development and therapeutic targets of chrysin derivatives.

The natural flavonoid chrysin exhibits broad-spectrum bioactivity. However, its clinical utility is severely constrained by suboptimal potency and unfavorable pharmacokinetic properties. Rational chemical modifications, including site-specific derivatization, molecular hybridization, and metal complexation, have yielde...

Lei Ma, Liang-Yan Lu, Xiao-Xin Tong et al. · 0 citations
Open access Oct 2026

Rational design and synthesis of a novel cereblon ligand class enabling selective molecular glue and potent PROTAC.

The expansion of E3 ligands provides elemental value for the research and drug design of both molecular glues and proteolysis-targeting chimeras (PROTAC). This study first reports the rational design of a novel class of sulfur-incorporated CRBN ligands (SCLs) with enhanced binding affinity over classical immunomodulato...

Ren-Hong Sun, Yan Li, Xiao-Bao Yang · 0 citations
#protein folding Sep 2026

Design of a high-affinity IL-21 decoy receptor as a novel therapeutic strategy for autoimmune disorders.

Elevated levels of the pro-inflammatory cytokine Interleukin 21 (IL-21) contribute to the progression of autoimmune and inflammatory diseases by binding to its receptor (IL-21R) and activating detrimental signaling pathways in immune cells. Consequently, we developed a recombinant decoy receptor protein designed to com...

Sara Vazifeshenas, Z. Hajihassan, Seyed Shahriar Arab et al. · 0 citations
Open access Nov 2026

First conjugates based on a Sigma receptor modulator and a proteasome-impairing agent. Design, synthesis and exploratory biological evaluation in cancer cells.

Cancer cells rely on a finely tuned proteostasis network to cope with high metabolic and proliferative demands. Targeting this vulnerability through the simultaneous modulation of both Sigma receptors (SRs) subtypes (i.e. S1R and S2R) and proteasome function represents an attractive and unprecedented strategy for the d...

G. Rossino, Sara Salvi, L. Molteni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.